This article explores the correlation between Gal-3, Klotho, calcium and phosphorus metabolism indicators and cardiovascular disease in non dialysis CKD (stage 3-5) patients, summarizes their clinical characteristics, and provides a basis for the prevention and treatment of cardiovascular disease caused by CKD in clinical practice, providing reference for related research. This article selects 100 patients with stage 3-5 CKD who have not received renal replacement therapy. This question involves collecting general data from patients, collecting blood samples from patients, detecting serum calcium, serum phosphorus, Gal-3, and PTH levels at different stages, and calculating the product of calcium and phosphorus. Meanwhile, this study compared the incidence of hypocalcemia, hyperphosphatemia, and hyperparathyroidism at different stages. The research results showed that there was no statistically significant difference in blood calcium levels between CKD3 patients in stages 3 and 4 (P>0.05), but the blood calcium levels of CKD3 patients were significantly lower than those in stages 3 and 4. The difference between the two groups was statistically significant (P<0.05). The calcium and phosphorus products and PTH of patients in different stages gradually increased, but there was no significant difference in ALP levels in different stages (P>0.05). The incidence of hypocalcemia, hyperphosphatemia, high PTH, and calcium phosphate products>55 showed significant differences (P<0.01), and showed an increasing trend with stages, with the lowest in stage 3 and the highest in stage 5. This article analyzes the serum levels of Gal-3, Klotho, and calcium and phosphorus in non dialysis patients with CKD, which has important guiding significance for preventing cardiovascular complications, early intervention, and reducing patient mortality.